title: Association of monocyte to HDL cholesterol level with contrast induced nephropathy in STEMI patients treated with primary PCI.
abstract: BACKGROUND
  Contrast induced nephropathy (CIN) has been proven to be a clinical condition related to adverse cardiovascular outcomes. In recent studies, the monocyte to high density lipoprotein ratio (MHR) has been postulated as a novel parameter associated with adverse renal and cardiovascular outcomes. In this study we investigated the association of MHR with CIN in ST-segment elevation myocardial infarction (STEMI) patients treated with primary percutaneous coronary intervention (PCI).
  
  
  METHODS
  Consecutive STEMI patients treated with primary PCI were prospectively recruited. Subjects were categorized into two groups; as patients who developed CIN (CIN+) and patients who did not develop CIN (CIN-) during hospitalization. CIN was defined as either a 25% increase in serum creatinine from baseline or 44.20 µmol/L increase in absolute value, within 72 h of intravenous contrast administration.
  
  
  RESULTS
  A total number of 209 patients were included in the study. Thirty-two patients developed CIN (15.3%). In the CIN (+) patients, monocytes were higher [1.02 (0.83-1.39) vs. 0.69 (0.53-0.90) 109/L, p<0.01] and HDL cholesterol levels were lower [0.88 (0.78-1.01) vs. 0.98 (0.88-1.14) mmol/L, p<0.01]. In addition, MHR was significantly higher in the CIN (+) group [1.16 (0.89-2.16) vs. 0.72 (0.53-0.95) 109/mmol, p<0.01]. In multivariate logistic regression analysis, MHR, Mehran score, AGEF score and CV/eGFR were independently correlated with CIN.
  
  
  CONCLUSIONS
  Higher MHR levels may predict CIN development after primary PCI in STEMI patients.
authors.forename: Saim
authors.initials: S
authors.lastname: Sağ
authors.forename: Abdülmecit
authors.initials: A
authors.lastname: Yıldız
authors.forename: Aysel
authors.initials: A
authors.lastname: Aydin Kaderli
authors.forename: Bülent Cuma
authors.initials: BC
authors.lastname: Gül
authors.forename: Ömer
authors.initials: Ö
authors.lastname: Bedir
authors.forename: Ercan
authors.initials: E
authors.lastname: Ceğilli
authors.forename: Bülent
authors.initials: B
authors.lastname: Özdemir
authors.forename: Fatma Ezgi
authors.initials: FE
authors.lastname: Can
authors.forename: Ali
authors.initials: A
authors.lastname: Aydınlar
mesh_terms: D000368:Aged; D008076:Cholesterol, HDL / Q000097:blood*; D003287:Contrast Media / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000166:cytology*; D062645:Percutaneous Coronary Intervention; D012372:ROC Curve; D000072657:ST Elevation Myocardial Infarction / Q000175:diagnosis / Q000628:therapy*
chemical_list: D008076:Cholesterol, HDL; D003287:Contrast Media